Last reviewed · How we verify

EV71 (inoculation vaccine)

Shandong Province Centers for Disease Control and Prevention · FDA-approved active Biologic

EV71 vaccine stimulates the immune system to produce antibodies and cellular immunity against Enterovirus 71, preventing infection and disease.

EV71 vaccine stimulates the immune system to produce antibodies and cellular immunity against Enterovirus 71, preventing infection and disease. Used for Prevention of Enterovirus 71 infection and hand, foot, and mouth disease (HFMD).

At a glance

Generic nameEV71 (inoculation vaccine)
SponsorShandong Province Centers for Disease Control and Prevention
Drug classinactivated viral vaccine
TargetEnterovirus 71 (EV71) viral antigens
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

The vaccine contains inactivated or attenuated EV71 virus particles that trigger both humoral (antibody) and cell-mediated immune responses. Upon exposure to wild-type EV71, the primed immune system recognizes and neutralizes the virus, preventing viral replication and the development of hand, foot, and mouth disease (HFMD) and its severe neurological complications.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: